Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa
Author Information
Author(s): Lee Phil Hyu, Kim Han-Soo, Lee Ji E., Choi Youjeong, Hong Jin Yong, Nam Hyo Suk, Sohn Young H., Kim Hyun Ok
Primary Institution: Yonsei University College of Medicine
Hypothesis
Levodopa-induced hyperhomocysteinemia leads to a change in EPC levels.
Conclusion
EPC levels were significantly decreased in PD patients treated with levodopa compared to those treated with levodopa/COMT inhibitors.
Supporting Evidence
- EPC levels were significantly lower in PD patients treated with levodopa compared to those treated with levodopa/COMT inhibitors.
- Homocysteine levels were significantly higher in PD patients treated with levodopa.
- Homocysteine was an independent predictor of the highest tertile of EPC levels.
Takeaway
This study found that patients with Parkinson's disease who take levodopa have fewer endothelial progenitor cells, which are important for blood vessel health.
Methodology
The study measured circulating EPCs in PD patients treated with either levodopa or levodopa/COMT inhibitors using flow cytometry.
Potential Biases
Potential confounding factors such as dietary habits and physical activity were not fully controlled.
Limitations
The sample size was small and varied, which may limit the validity of the conclusions.
Participant Demographics
53 PD patients (28 treated with levodopa, 25 with levodopa/COMT inhibitors) and 23 healthy controls.
Statistical Information
P-Value
0.007
Confidence Interval
95% CI: 0.584–0.961
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website